06:19:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-10-31 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning LUMITO 0.00 SEK
2024-05-07 Kvartalsrapport 2024-Q1
2024-05-07 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-10-31 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning LUMITO 0.00 SEK
2023-05-25 Årsstämma 2023
2023-05-03 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-02 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-30 Ordinarie utdelning LUMITO 0.00 SEK
2022-05-27 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-24 Extra Bolagsstämma 2021
2021-10-20 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning LUMITO 0.00 SEK
2021-05-27 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning LUMITO 0.00 SEK
2020-05-27 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-02-17 Bokslutskommuniké 2019
2019-10-31 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-06-04 Årsstämma 2019
2019-05-23 Ordinarie utdelning LUMITO 0.00 SEK
2019-04-30 Kvartalsrapport 2019-Q1
2019-02-15 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Lumito specialiserar sig på medicinsk teknik för digital patologi. Bolaget strävar efter att förbättra vävnadsdiagnostiken med sin patenterade teknologi baserad på uppkonverterade nanopartiklar. Bolaget planerar att initialt lansera sin första produkt för forskningslaboratorier. Bolaget bildades under 2010 som en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.
2023-11-29 08:00:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

Today, 29 November 2023, the subscription period begins in Lumito AB:s (publ) ("Lumito" or the "Company") issue of units consisting of warrants of series TO5 and TO6 with preferential right for existing shareholders (the "Issue"), which the board of directors resolved on November 10, 2023 (changes to the terms and conditions for the Issue were resolved and announced on November 17, 2023). The subscription period in the Issue runs from and including November 29, 2023, up to and including December 13, 2023. However, note that some banks and nominees may have an earlier deadline for subscription in the Issue. Shareholders should therefore check with their bank or nominee if they have an earlier deadline for subscription.

Time table

November 29, 2023 – December 8, 2023Trading in unit rights (UR) on NGM Nordic SME
November 29, 2023 – December 13, 2023Subscription period for the Issue
November 29, 2023 – approximately week 52, 2023Trading in paid subscribed units (BTU) on Nasdaq First North Premier Growth Market
December 15, 2023Estimated day for announcement of outcome

Subscription with preferential rights
The shareholders who, on the record date of November 27, 2023, were registered in the share register maintained by Euroclear Sweden AB ("Euroclear") and on behalf of the Company, directly registered shareholders, receive a preprinted issue report with attached payment advice from Euroclear. In the event that a different number of unit rights than those stated in the preprinted issue report are used for subscription the special application form, which is available on Mangold's website emission.mangold.se, shall be used as a basis for subscription through cash payment.

Shareholders whose holdings of shares in the Company were nominee-registered with a bank or other nominee on the record date do not receive an issue report or a special application form from Euroclear. Subscription and payment must then instead take place in accordance with instructions from the respective trustee.

Subscription without preferential rights
Only those who have subscribed for units with the support of unit rights (regardless of whether they were shareholders on the record date or not) have the right to subscribe for additional units without the support of unit rights, i.e. without preferential rights. Notification of subscription without preferential rights by a nominee is made in accordance with instructions from the respective nominee. For subscription through an endowment insurance or an investment savings account, please contact your nominee. Application for subscription without preferential rights in other respects is done by sending an application form by e-mail to Mangold or alternatively by electronic subscription with Bank ID on Mangold's website. Application form and electronic subscription are available on Mangold's website emission.mangold.se.

Advisers
Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor Lumito in connection with the Issue.